Drugs / AAV8.hLCA5
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT05616793 | Jun 2023 → Jun 2028 expected | Leber congenital amaurosis 5 | Opus Genetics, Inc | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AAV8.hLCA5 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05616793 ↗ |
| Modality | Gene therapy (AAV / viral vector) | “Adeno-associated virus vector expressing human LCA5 gene” NCT05616793 ↗ |
| Route | Other | “subretinal injection” NCT05616793 ↗ |